Timeline

2024

Over 3 million bottles of cepoLAB sold
Cumulative sales surpass KRW 100 billion

2023

Over 1 million bottles of cepoLAB sold
Selected as “Outstanding Technology in Biotechnology and Chemistry” by Korea Biomedical Review
Cumulative sales exceed KRW 50 billion

2018~2020
“Commercialization
Phase”

[2020]
Developed anti-inflammatory candidate for chronic diseases (joint research with Gyeonggi Bio Center)
First global commercialization of functional ingredient Ceriporia
Launched Cepona for blood glucose support
[2019]
Completed GMP manufacturing plant for functional ingredients
Acquired functional health ingredient certification for Ceriporia (KFDA)
Demonstrated support for insulin resistance
[2018]
Launched cosmetic line cepoLAB
Acquired pre-approval for functional use of Ceriporia in glucose metabolism (KFDA)
Developed FBCA01, a novel immune-enhancing compound

2014~2017
“Product Development
& Research Expansion”

[2017]
Registered 5 additional patents for CLEPS® in dermatological applications
[2016]
Fugenbio established (corporate spin-off)
Registered 11 new patents for Ceriporia
Registered 3 global patents for blood glucose support
[2015]
Completed human trials for Ceriporia blood sugar effect (Kyunghee University Hospital)
Developed CLEPS® (Cosmetic bioactive extract from Ceriporia)
[2014]
Completed 2nd round of animal testing

2005~2013
“Discovery of Blood Glucose
Support Effect”

[2013]
Completed first animal and human trials (Kyunghee University Hospital)
[2011]
Ceriporia patent registered
[2010]
Identified blood glucose-lowering potential of Ceriporia
[2005]
Founded Fugenceltic (initial biotech research entity)